Article
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.
Antimicrobial agents and chemotherapy - 1 Sept 2016
Yu Xia, Wang Guirong, Chen Suting, Wei Guomei, Shang Yuanyuan, Dong Lingling, Schön Thomas, Moradigaravand Danesh, Parkhill Julian, Peacock Sharon J, Köser Claudio U, Huang Hairong
Abstract excerpt
Antofloxacin (AFX) is a novel fluoroquinolone that has been approved in China for the treatment of infections caused by a variety of bacterial species. We investigated whether it could be repurposed for the treatment of tuberculosis by studying its in vitro activity. We determined the wild-type and non-wild-type MIC ranges for AFX as well as ofloxacin (OFX), levofloxacin (LFX), and moxifloxacin (MFX), using the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.